HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Vitamin D Help For Type 2 Diabetes Prevention Doubted In NIH-Backed Study

Executive Summary

Clinical trial found that by two and a half years, a cohort of subjects who took 4,000 IU vitamin D daily were not at significantly lower risk of developing type 2 diabetes than a placebo group, dampening hopes from previous studies suggesting it could lower risk up to a third.

You may also be interested in...



US Wellness Market In 2019: Amarin Wins, Loses On Supplements; Gottlieb Leaves With Consumer Health Flourish

Looking look back on US wellness market developments and events in 2019, HBW Insight finds a firm that doesn’t compete in the dietary supplement sector, Amarin, made a good bit of news that affected the industry during the year. We track news across the wellness space from the past year.

Analysis Finding Low Cardio Benefit From Nutrients Has Critics In Industry, Science

Meta-analysis finds omega-3 and folate can benefit heart-related health, but says association is weak and a combination of calcium and vitamin D may increase risk of stroke. CRN says study is a “coordinated, all-out assault on nutrition” with “major” limitation of omitting epidemiological studies.

Research & Development In Brief

Fish rich in omega-3s protect women’s hearts; low vitamin D linked to insulin resistance; omega-3s do not relieve depression; and hepcidin levels could reveal iron deficiency

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS149081

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel